Silexion Therapeutics Corp - 8-K Filing
Silexion Therapeutics initiated GMP clinical supply manufacturing of its siRNA therapy SIL204 with Catalent at a European facility and received approval for the Phase 2/3 trial from Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee. The drug product is being manufactured in Limoges, France, to support first patient dosing in locally advanced pancreatic cancer. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits (d) Exhibits 99)
Tickers: $SLXN